Quantcast
Last updated on April 18, 2014 at 7:15 EDT

Latest Cannabinoids Stories

2013-08-05 04:21:36

-Recent Nasdaq Listing Further Enhances Robust Financial Position; Sativex Continues to Progress in Late-Stage Clinical Trials in U.S.- LONDON, Aug. 5, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the third quarter ended 30 June 2013....

2013-08-05 04:21:34

-Provides Further Evidence of Long-term Efficacy- LONDON, Aug. 5, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces top-line results from a 12 month placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS). The study results...

2013-07-31 23:36:43

Exercise, the cannabinoid system and human evolution are the focus of a new posting on The Compassion Chronicles by political scientist Bryan W. Brickner, who highlights President Bush’s thoughts on running, the health benefits of exercise, and the science of cannabinoids and the runner’s high in an excerpt from his forthcoming book, The Book of the Is: A book on bridges (Summer 2013). Chicago, IL (PRWEB) July 31, 2013 Exercise, the cannabinoid system and human evolution are the focus...

2013-07-22 04:20:41

LONDON, July 22, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure (MRP) seeking to expand the marketing authorization for Sativex® into France for the treatment of spasticity due to Multiple...

2013-07-15 04:20:56

LONDON, July 15, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 August 2013 its financial results for the third quarter ending 30 June, 2013. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT). Conference call information will be provided...

2013-07-11 12:28:08

AMSTERDAM, CAMBRIDGE, England and CLINTON, New Jersey, July 11, 2013 /PRNewswire/ -- Echo Pharmaceuticals ("Echo") announces that Namisol(R) has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis (MS). The trial has been conducted by the Centre for Human Drug Research (CHDR) in the VU University Medical Center Amsterdam and it was led by Dr. G.J. Groeneveld, Research Director Neurology & Pain, CHDR. The...

2013-07-08 04:21:40

LONDON, July 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, is pleased to note the announcement from its partner Almirall S.A. that Sativex® is now available in Italy as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS)...

2013-06-03 04:21:08

-Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST- LONDON, June 3, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the second quarter and half year ended 31 March 2013. CORPORATE HIGHLIGHTS Initial public offering on the NASDAQ Global...

Marijuana May Help Protect, Heal Brain Cells
2013-05-30 16:21:42

Michael Harper for redOrbit.com — Your Universe Online A new study from Tel Aviv University has found that THC, the psychoactive component in marijuana, can protect the brain from cognitive damage, especially following injury. Medical marijuana has been found to be beneficial in treating pain, insomnia and lack of appetite, but this study has found that THC also helps the brain protect itself before and after an injury. Professor Yosef Sarne at Tel Aviv University's Adelson...

2013-05-14 16:27:32

Company's Growth and Expansion Allows Immediate Access to Funding and Exclusive Partnership SANTA ANA, Calif., May 14, 2013 /PRNewswire/ -- Latteno Food Corp.'s (OTCPink: LATF) wholly-owned subsidiary Green Cannabis, today announced the release of new roll-out medical marijuana edible products consisting of our own private label Peanut Butter Cup, Chocolate Bar and Chocolate Chip Cookie all made out of Cannabutter. These are Endocannabinoid CBD Edibles: Peanut Butter Cups consist...